Spes Immunotherapeutics is a biotech startup dedicated to revolutionizing cancer care through cutting-edge precision immunotherapies. Founded upon groundbreaking research in oncology and immunology, we are committed to developing highly targeted therapies aimed at providing lasting solutions to some of the most aggressive cancers.
Headquartered in Barcelona, a dynamic hub for biotechnology innovation, our multidisciplinary team combines deep scientific expertise and strategic vision to rapidly translate promising science into transformative clinical outcomes. At Spes, we envision a future where cancer relapse is no longer inevitable, but preventable—enabling patients to live healthier, fuller lives.
Join us as we advance innovative therapies designed to redefine standards of care in oncology.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Cosymbio Lab, Barcelona,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Potential Plus Ltd.
- HQ
- Barcelona
Spes Immunotherapeutics Questions
Spes Immunotherapeutics's LinkedIn profile is https://es.linkedin.com/company/spes-immunotherapeutics
Spes Immunotherapeutics has
2 employees.
View email and phone details for 2
employees at Spes Immunotherapeutics.
Spes Immunotherapeutics's industry is
Biotechnology Research
Spes Immunotherapeutics's top competitors are
St. Jude Children's Research Hospital,
Clarametyx Biosciences,
Bcome.,
Potential Plus Ltd,
Bioexpert Network,
Biotheia,
Aithyra Research Institute For Biomedical Artificial Intelligence,
Op2lysis,
Clinology,
Resilient Collective.
Spes Immunotherapeutics's categories are Biotechnology Research
Spes Immunotherapeutics's founding year is 2025
